Evaluation of sNfL in MS patients with NEDA-3

sNfL predicts NEDA-status in a 6-year longitudinal cohort of MS patientsПодробнее

sNfL identifies patients at higher risk of future disease activity beyond NEDA-3 statusПодробнее

The predictive value of NEDA-3 for long-term disability in MSПодробнее

sNfL and Radiologic Disease Activity in Patients With MSПодробнее

Serum neurofilament light chain levels as a biomarker in MSПодробнее

Post Hoc Analysis: Phase 3 EXPAND Trial in Secondary Progressive MSПодробнее

No evidence of disease activity as a predictive measure of long-term disability in RRMSПодробнее

No Evidence Of Disease Activity (NEDA): the goal of Multiple Sclerosis (MS) treatmentПодробнее

NEDA-3 and treatment goalsПодробнее

Serum NfL: a first-in-class biomarker paving the way towards precision medicine in MSПодробнее

Aiming for No Evidence of Disease Activity (NEDA) in multiple sclerosis (MS)Подробнее

Neuropsych Evaluation in MS - National MS SocietyПодробнее

MS education: How balance therapy helps those with multiple sclerosis | Ohio State Medical CenterПодробнее

Tanuja Chitnis, MD: Nfl Levels In Long-Term MS OutcomesПодробнее

The Progression of Multiple Sclerosis in Young Women and NEDAПодробнее

Moving towards precision medicine in MS with sNfLПодробнее

What is NEDA and How Does it Help Patient CareПодробнее

Understanding Multiple Sclerosis: Diagnosing MS and Evaluating Disease ActivityПодробнее

Interpretation of serum NfL depends on the selection of a reference populationПодробнее